Lisanti Capital Growth, LLC Blueprint Medicines Corp Transaction History

Lisanti Capital Growth, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 05, 2019	SELL	$73.54 - $97.8 $1.92 Million - $2.56 Million	-26,150 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$48.7 - $86.6 $1.27 Million - $2.26 Million	26,150 New	26,150 $2.09 Million
Q2 2018 Aug 13, 2018	SELL	$60.96 - $101.18 $1.52 Million - $2.52 Million	-24,860 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $414,032 - $581,667	5,650 Added 29.41%	24,860 $2.28 Million
Q4 2017 Feb 07, 2018	BUY	$62.91 - $88.32 $315,493 - $442,924	5,015 Added 35.33%	19,210 $1.45 Million
Q3 2017 Nov 13, 2017	BUY	$42.37 - $69.67 $601,442 - $988,965	14,195	14,195 $989,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.39B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

Stay updated on Lisanti Capital Growth, LLC with notifications on news.